Copyright benzinga
Analysts are saying that Abbott Laboratories could fall by 2030. Bullish on ABT? Invest in Abbott Laboratories on SoFi with no commissions. If it’s your first time signing up for SoFi, you’ll receive up to $1,000 in stock when you first fund your account. Plus, get a 1% bonus if you transfer your investments and keep them there until December 31, 2025. Abbott Laboratories (ABT) is a longtime leader in medical devices, but it’s been challenged to make up for weaknesses in its nutrition and diagnostics divisions. The company is working to bring more devices to market, but investors are wondering if its current issues are temporary or longer lasting. In this article, we’ll look at ABT’s latest share price, Wall Street sentiment, multiyear price forecasts, and the key factors that are playing a critical role in the company’s path going forward. Current Stock Overview Market Cap: $216.57 billion Trailing P/E Ratio: 16.69 Forward P/E Ratio: 23.36 1-Year Return: 10% 2025 YTD: 10% Shares of Abbott are trading around $124 per share thanks to a moderate gain over the last year. The stock is trading midway between its 52-week high and low, but shares have dropped a bit since the company released its Q3 results on Oct. 15. Abbott missed quarterly revenue estimates, as it faces new tariffs, a U.S. foreign aid freeze and a significant decline in demand for COVID-19 tests, which were once a strong source of revenue. The company's medical devices segment, which includes heart devices, did beat estimates, but its nutrition unit fell short on weakness in baby formula products. The company also has to contend with stiff competition for other medical devices Medtronic (MDT) and Boston Scientific (BSX), which siphon off market share if Abbott isn’t able to innovate quickly enough. ABT is a consensus Buy with a price target of $143 based on the ratings of 23 analysts, according to Benzinga. The high target is $162 from Barclays on Oct. 17, 2025. The low is $120 from Jefferies on Sept. 26, 2024. The three most-recent targets from Barclays, Raymond James, and Evercore ISI Group average $150 with an implied 19% upside. Quick Snapshot Table of Predictions & Methodology for Forecasting Bull & Bear Case Abbott is showing strength in its core medical devices unit, but other segment shortfalls are cutting into overall revenue. Abbott’s medical devices represent most of its revenue and continue to grow at a fast rateThe company continues to create new medical devices to boost its offerings and revenueAbbott offers essential healthcare products, which can help it weather economic uncertainty better than most stocks COVID-19 test sales continue to decline, which can make high growth rates more difficult to achieveAbbott faces significant competition in the medical devices industryThe FDA can regulate the industry or require recalls, which can adversely affect Abbott’s revenue Stock Price Prediction for 2025 CoinCodex projects moderate gains in 2025, but the lowest price target suggests ABT stock will stay right where it is. The company’s growing medical device sales and any progress with its upcoming medical device launches can lead to a higher stock price. Stock Price Prediction for 2026 CoinCodex projects a moderate decline in ABT stock next year. Declining COVID-19 test sales may continue to weigh on the stock, and if the FDA requires the company to recall more of its products, ABT stock may lose value. Stock Price Prediction for 2030 CoinCodex anticipates a moderate decline in ABT stock in 2030. Competitors like Medtronic and Boston Scientific may take market share and innovate at a faster rate. However, ABT stock can rise past these forecasts if its medical devices continue to generate high year-over-year sales growth. Investment Considerations Abbott is a longstanding healthcare giant that has endured various economic cycles. The stock may be suitable for dividend income investors who want some growth opportunities. Abbott’s ability to produce leading medical devices is its biggest strength, but it is a crowded field. COVID-19 test sales are well in the rearview mirror, so the company will have to pursue new growth opportunities to generate sizable growth rates in the future. Frequently Asked Questions
